Prostate‐specific antigen in acute hepatitis and hepatocellular carcinoma

Prostate‐specific antigen (PSA) is the most important tumor marker in prostate cancer diagnosis and follow‐up. Its catabolism by the liver has not influenced its use as a prostate marker until the recent report of a significant increase in a man and a woman with acute hepatitis. In addition, PSA was detected in liver tumor extracts, which warranted its evaluation in liver cytolysis and hepatocellular carcinoma. In this study, PSA was evaluated in a cohort of both sexes presenting either acute hepatitis or hepatocellular carcinoima.

[1]  E. Diamandis,et al.  Prostate-specific Antigen: Its Usefulness in Clinical Medicine , 1998, Trends in Endocrinology & Metabolism.

[2]  G. Larcos,et al.  Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation. , 1998, AJR. American journal of roentgenology.

[3]  V. Sriuranpong,et al.  Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. , 1998, American journal of clinical oncology.

[4]  C. López-Otín,et al.  Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. , 1998, Endocrine reviews.

[5]  E. Ulusoy,et al.  Effect of postnecrotic and alcoholic hepatic cirrhosis on development of benign prostatic hyperplasia , 1998, The Prostate.

[6]  E. Diamandis,et al.  Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  N. Després,et al.  Antibody interference in thyroid assays: a potential for clinical misinformation. , 1998, Clinical chemistry.

[8]  X. Bosch,et al.  Increased serum prostate-specific antigen in a man and a woman with hepatitis A. , 1997, The New England journal of medicine.

[9]  J. Eastham,et al.  Influence of hepatic function on serum levels of prostate specific antigen. , 1997, The Journal of urology.

[10]  L. Denis,et al.  The European randomized study of screening for prostate cancer , 1997, Cancer.

[11]  E. Diamandis,et al.  Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. , 1997, British Journal of Cancer.

[12]  R. A. Jackson,et al.  Misleading results from immunoassays of serum free thyroxine in the presence of rheumatoid factor. , 1997, Clinical chemistry.

[13]  H. Carter,et al.  Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. , 1997, The Urologic clinics of North America.

[14]  J. Ignatoff.  Re: Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. , 1997, The Journal of urology.

[15]  T. Stamey,et al.  The periurethral glands do not significantly influence the serum prostate specific antigen concentration. , 1996, The Journal of urology.

[16]  D. Culkin,et al.  Prostate specific antigen is metabolized in the liver. , 1996, The Journal of urology.

[17]  M. Brawer,et al.  Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. , 1995, Urology.

[18]  E. Diamandis,et al.  Prostate-specific antigen and lack of specificity for prostate cells , 1995, The Lancet.

[19]  E. Diamandis,et al.  New biological functions of prostate-specific antigen? , 1995, The Journal of clinical endocrinology and metabolism.

[20]  J. Reinsberg.  Interference by human antibodies with tumor marker assays. , 1995, Hybridoma.

[21]  L. Baert,et al.  Immunohistochemical localization of prostate-specific markers within the accessory male sex glands of Cowper, Littre, and Morgagni. , 1994, Urology.

[22]  D. Assimos,et al.  Effects of hemodialysis on prostate-specific antigen. , 1993, Urology.

[23]  C G Chute,et al.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. , 1993, JAMA.

[24]  M. Benson,et al.  The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. , 1992, The Journal of urology.

[25]  L. I. Stowell,et al.  An enzyme-linked immunosorbent assay (ELISA) for prostate-specific antigen. , 1991, Forensic science international.

[26]  J. Oesterling,et al.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.

[27]  J. Hornberger,et al.  Prostate-specific antigen is not excreted by human kidney or eliminated by routine hemodialysis. , 1991, Urology.

[28]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[29]  M. Roggendorf,et al.  Demonstration of a transient rheumatoid factor in the acute phase of hepatitis non A, non B , 1985, Journal of medical virology.

[30]  G. Salama,et al.  Influence of digital rectal massage on urinary prostate‐specific antigen: Interest for the detection of local recurrence after radical prostatectomy , 1998, The Prostate.

[31]  E. Diamandis,et al.  Prostate‐Specific antigen expression by various tumors , 1995, Journal of clinical laboratory analysis.

[32]  J. Beatty,et al.  Human anti-murine antibody interference in measurement of carcinoembryonic antigen assessed with a double-antibody enzyme immunoassay. , 1991, Clinical chemistry.

[33]  T. Weber,et al.  Endogenous interference in imunoassays in clinical chemistry. A rewiev , 1990 .

[34]  T. Weber,et al.  Endogenous interference in immunoassays in clinical chemistry. A review. , 1990, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[35]  L. Boscato,et al.  Heterophilic antibodies: a problem for all immunoassays. , 1988, Clinical chemistry.

[36]  Williams Rc.  Rheumatoid factors in subacute bacterial endocarditis and other infectious diseases. , 1988 .